SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

IMTX

https://immatics.com/
MIXED
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The EPS beat is overshadowed by the revenue collapse and widening net loss. The key catalyst is the SUPRAME Phase 3 data trigger in 2026, a positive readout would validate the commercial thesis and could drive a 50%+ move. Monitor ASCO 2026 presentations for IMA203CD8 and IMA402 data as near-term sentiment drivers. The $521.5M cash runway into 2028 provides a long execution window, reducing near-term financing risk.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.39
T+0 close · May 12, 2026 · via day close
Latest settled
−17.30%
T+60 · $9.42
Vs SPY
−21.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $11.39entry
  2. T+1 · 6mo ago −5.27%α −5.84% · $10.79
  3. T+5 · 6mo ago −6.76%α −6.84% · $10.62
  4. T+20 · 5mo ago −22.12%α −20.40% · $8.87
  5. T+60 · 3mo ago −17.30%α −21.68% · $9.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immatics reported Q1 2026 EPS of -$0.29, a 33.9% beat vs consensus of -$0.44, but revenue fell sharply to $8.7M from $21.4M YoY due to lower collaboration cost recognition. The net loss widened to $66.5M from a prior-year net profit of $45.9M, driven by higher R&D spending on the SUPRAME Phase 3 trial and early commercial preparations. The stock's move will hinge on the upcoming SUPRAME interim/final analysis triggers in 2026 and multiple ASCO data readouts, not the mixed quarterly financials.

Key Financial Metrics

EPS
−$0.29
est −$0.44 · +34.1%
Revenue
$8.7M
est $10.4M · -16.4% · -59.4% YoY
Rating
miss

Key Facts

  • EPS of -$0.29 beat consensus of -$0.44 by 33.9%
  • Revenue of $8.7M declined 59.3% YoY from $21.4M due to lower collaboration cost recognition
  • Net loss of $66.5M vs net profit of $45.9M in Q1 2025
  • Cash and financial assets of $521.5M as of March 31, 2026, with cash reach projected into 2028
  • SUPRAME Phase 3 interim and final analyses expected to be triggered in 2026
  • BLA submission expected in H1 2027 with commercial launch in H2 2027
  • Multiple ASCO 2026 data readouts across PRAME cell therapy and bispecific programs
  • R&D expenses rose 41.3% YoY to $68.1M driven by SUPRAME trial costs
  • Completed at-the-market offering of $24.4M net proceeds in Q1 2026

Financial Impact

Revenue decline of $12.7M YoY and net loss swing of $112.4M from profit to loss; cash burn of ~$42M in operating cash flow for the quarter

revenuenet incomeoperating cash flowR&D expenses

Risk Factors

  • SUPRAME Phase 3 trial may fail to meet PFS or OS endpoints, destroying the commercial thesis
  • Revenue is lumpy and dependent on collaboration milestones, not recurring
  • Net loss is widening rapidly with R&D spend increasing 41% YoY
  • Dilution risk from at-the-market offering program

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292675

Track record

23 reports on IMTX

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026